STUDY QUESTION: What is the association between placental formyl peptide receptor 2 (FPR2) and trophoblast and endothelial functions in pregnancies affected by foetal growth restriction (FGR)?
Introduction
Foetal growth restriction (FGR) is one of the most significant healthcare issues globally. It is a major cause of late pregnancy stillbirth, a leading cause of neonatal death and morbidity (Breeze and Lees, 2007) , and a major contributor to infant prematurity. Many FGR survivors suffer lifelong impairment including cerebral palsy, stroke, retinopathy and an increased risk of chronic adult diseases such as hypertension, ischaemic heart disease and diabetes (Pedersen et al., 2008) . Thus, FGR has potentially whole-of-life consequences for an individual's health, and therefore has a major impact on human population health. Severe FGR is defined as a birthweight of less than the fifth percentile for gestational age. Evidence of an additional pathology, including asymmetric growth and a reduced amniotic fluid index, allows clinicians to discriminate between FGR and small for gestational age (SGA) babies that are otherwise healthy (Dashe et al., 2000) . Idiopathic FGR cases are associated with 'placental insufficiency', which occurs with impairments in placental development leading to reduced uterine artery blood flow into the placenta or failure of maternal blood volume expansion or other vascular adaptations that are appropriate by mid-pregnancy (Krebs et al., 1996) . In FGR, placentae are often smaller, and have significant morphological and functional defects. For example, there is reduced trophoblast proliferation (Chen et al., 2002) , increased apoptosis (Heazell et al., 2011) and abnormal villous vasculature with less branched terminal villi (Krebs et al., 1996) . Defective trophoblast and endothelial functions reduce transfer of nutrients and growth factors to the foetus, restricting its growth. Therefore, it is important to understand the molecular mechanisms underlying human FGR.
During the first trimester of human pregnancy, the mononuclear villous cytotrophoblasts (VCTs) in the floating villi continue to proliferate and differentiate into the multinucleated syncytiotrophoblast (ST). The ST layer plays a critical role throughout pregnancy, including nutrient and ion exchange and the synthesis of hormones required for foetal growth and development (Larque et al., 2013) . Thus, a syncytium that functions efficiently requires both fusion and differentiation of VCTs, and dysfunctional VCT proliferation and differentiation leads to increased ST apoptosis, which is a hallmark of the pathogenesis of human FGR (Heazell et al., 2011) .
VCT functions are influenced by multiple regulatory factors, including receptor proteins, adhesion molecules, growth factors, cytokines, proteases, matrix-derived components, transcription factors and oxygen tension (Roberts et al., 2004) . We are interested in investigating the expression and functional role of a seven trans-membrane receptor protein called formyl-peptide receptor (FPR) that belongs to the G-protein coupled receptor (GPCR) family. Members of the GPCR family are important regulators of basic cellular, physiological and immune functions during embryogenesis and organogenesis (Waller-Evans et al., 2010) . In humans, three FPR protein paralogs have been identified (FPR1, FPR2 and FPR3) . Their activation by specific agonists leads to transient calcium fluxes, extracellular signal-regulated kinase (ERK) phosphorylation and chemotaxis (Schepetkin et al., 2014) . Of these, FPR2 is unique as it uses both lipid and protein ligands. Most of the FPR2 agonists are peptides, with the exception of the eicosanoid, lipoxin A4 (LXA4) and of the synthetic small-molecular weight ligands isolated by compound library screens. Activation of FPR2 by specific ligands improves basic cellular functions including proliferation, differentiation, invasion and angiogenesis as well as host defence and the regulation of inflammatory reactions (Cattaneo et al., 2013) , which are important for the growth and function of the human placenta. Studies on targeted deletion of Fpr2 in mice and/or in vitro silencing of human FPR2 have demonstrated that FPR2/Fpr2 gene inactivation/deletion was associated with increased inflammation, compromised immune regulation and abnormal vessel growth, whereas FPR2 activation or over-expression inhibited inflammation, and restored immune regulation and neovascularization (Dufton et al., 2010 , Kao et al., 2014 .
FPR2 regulates inflammatory events in the human endometrium and decidua of early pregnancy; production of the pregnancy hormone hCG early in pregnancy and regulation of the inflammatory cascade associated with both physiological and pathological labour (Macdonald et al., 2011) . In a previous study, reduced expression of FPR2 and its association with increased inflammation during pregnancy were reported in the peripheral blood, placentae of women with preeclampsia (PE)-affected pregnancies and in a rat model of PE, suggesting that decreased FPR2/Fpr2 expression contributes to peripheral and placental inflammation in PE pregnancies (Xu et al., 2014) .
Increased inflammation is also associated with inadequate placental development and function in FGR (Cotechini et al., 2014) . However, whether FPR2 induced placental inflammation contributes to FGR is yet to be investigated. Therefore, the overall aim of this study was to investigate placental FPR2/Fpr2 expression in FGR and identify whether changes in placental FPR2/Fpr2 contribute to the pathophysiology of FGR. We hypothesized that reduced placental FPR2/Fpr2 expression contributes to abnormal placental cell function in FGR pregnancies. Firstly, we aimed to quantify placental expression of FPR2/Fpr2 using a clinically well-defined cohort of human FGR placentae and in a spontaneous FGR mouse model. In the second part of the study, using an in vitro cell culture model, we aimed to investigate the functional consequences of reduced FRP2 in term VCT on trophoblast proliferation, differentiation to ST, and on the mRNA and protein concentrations of the trophoblast differentiation marker, HCGB/β-hCG, and of inflammatory cytokines and chemokines. In the last part of the study, we also investigated the functional role of FPR2 on placental angiogenesis and endothelial cell (EC) permeability potential using human umbilical vein endothelial cells (HUVEC) in culture.
Materials and Methods

Human placental tissues
Placental tissues from pregnancies in first trimester and second trimester were obtained from elective terminations, after obtaining written informed consent. The placental tissues were collected with the approval of the University Hospital ethics committees at the Broussais Hospital (Paris, France), Grenoble University Hospital (Grenoble, France), and from Auckland Medical Aid Centre (AMAC, Auckland, New Zealand) with approval from the Northern Health and Disability Ethics Committee (NTX1206067AM05). Placental tissues were collected at 6-14 weeks of gestation (n = 12) and second-trimester pregnancies at 20 weeks of gestation (n = 4). Termination of pregnancy in second trimester was performed in control cases affected by severe bilateral or low obstructive uropathy or major cardiac abnormalities. The karyotype of placental cells was checked in all cases (free trisomy 21 or normal) (Malassine et al., 2008) .
Placentae from third-trimester pregnancies complicated by idiopathic FGR (n = 25) and those from gestation-matched pregnancies with appropriately grown infants as controls (n = 25) were collected following Caesarean section or vaginal delivery at a gestation range of 27-40 weeks. Placentae were collected with the approval of the Research and Ethics Committee of The Royal Women's Hospital, Melbourne. All samples were collected with written informed patient consent. Previous studies from our laboratory have described the clinical characteristics of both the FGR and gestation-matched control groups included in this study (Murthi et al., 2006; Borg et al., 2015) . Briefly, the inclusion criteria for the FGR study group were a birthweight of less than the 10th percentile for gestation as determined by the Australian foetal growth charts (Guaran et al., 1994) , and at least two of the following diagnoses on antenatal ultrasound: abnormal umbilical artery Doppler flow velocimetry, oligohydramnios (amniotic fluid index <7), or asymmetric growth of the foetus (head circumference-to-abdominal circumference ratio >95th centile for gestation). Exclusion criteria for both cases and control groups were factors that are known causes of FGR and included maternal smoking and drug dependency during pregnancy, other underlying maternal diseases such as gestational diabetes, PE, hypertension, placental abruption and prolonged rupture of membranes, foetal congenital anomalies and suspected intrauterine infection (Murthi et al., 2006) . Control pregnancies were selected to match FGR cases according to gestational ages.
Pre-term control placentae were collected from women presented in spontaneous idiopathic pre-term labour or who underwent elective delivery for conditions not associated with placental dysfunction (e.g. one patient included in this study delivered pre-term electively by Caesarean section because of maternal breast cancer). More specifically, control patients did not have clinical evidence of FGR, PE or ascending infection. All control patients gave birth to normally formed babies with birthweights appropriate for gestational age, and the placentae from these patients were also grossly normal (Murthi et al., 2006) . All samples were processed within 20 min of placental delivery, with tissues excised from randomly selected areas of central cotyledons following the removal by dissection of any attached decidua. Tissue pieces were thoroughly washed in 0.9% phosphate buffered saline (PBS) to minimize blood contamination, and then snap frozen and stored at -80°C for RNA and protein analysis or fixed in 10% formalin or 4% paraformaldehyde/PBS for immunolocalisation studies.
FPR2 siRNA treatment in cultured VCT and HUVEC VCTs were prepared from placentae obtained from uncomplicated term pregnancies (n = 6-12) with the approval of the Research and Ethics Committees of Mercy Hospital for Women and from Monash Health, Melbourne. VCTs were isolated as described previously. Briefly, trophoblasts were enriched by differential sequential trypsin digestion and the use of a Percoll gradient (20-60%). VCTs were cultured in DMEM supplemented with 10% foetal bovine serum (FBS), 2 mM glutamine, 100 μg/mL streptomycin and 100 IU/mL penicillin. The purity of VCT cultures was characterized by positive staining for CK7 (95% positive cells) and by microscopic observation of cell aggregates and ST formation at 48-72 h (Handschuh et al., 2007) .
HUVEC were freshly isolated from uncomplicated term pregnancies (n = 6 patients) and cultured as previously described (Lim et al., 2015) . Briefly, HUVEC were isolated following cannulation of the umbilical vein and enzymatic digestion of the vessel using collagenase Type 2 (Invitrogen, Australia) for 20 min at 37°C. The purity of HUVEC cells was determined by positive staining for von Willebrand factor (vWF) (98% positive cells).
Isolated cells were cultured and maintained in EGM2 complete media (LONZA Bioscience, Basel, Switzerland) with 10% FBS supplemented with 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin, and maintained in 5%CO 2 /21% O 2 .
VCT and HUVEC were seeded at a density of 2 × 10 5 cells/well in 6-well plates and treated with 100 nM FPR2 siRNA (siFPR2) (19-21 base pairs, Thermo Fisher Scientific, Waltham, MA, USA) using the Hiperfect transfection reagent (Invitrogen, Carlsbad, CA, USA). The optimum siRNA: RNAiFect ratio and incubation time for the culture were determined to be 1:6 and 72 h, respectively (data not shown). HUVEC were transfected as above for 48 h. Negative control siRNA (siCONT, 100 nM) used in these experiments consisted of an enzyme-generated pool of oligonucleotides (15-19 base pairs) that showed no DNA sequence similarity to any known human gene (AllStars Neg. siRNA AF 488, Qiagen, Hilden, Germany) (Borg et al., 2015) . At the end of the incubation period, the cells and media were collected separately for analysis of gene and protein expression. For studies on proliferation of HUVEC, the cells were seeded at a density of 2 × 10 4 cells/ well in 96-well plates.
Placental Fpr2 mRNA in a spontaneous FGR mouse model
Timed matings between 12-week-old female CBA/CaH.Arc and male CBA/CaH.Arc and DBA/2 J.Arc mice purchased from the Animal Resource Centre (Murdoch, Australia) were undertaken. Animal experiments were performed in accordance with the guidelines, and with approval from the Northern Sydney local Health District Animal Ethics Committee (ACEC#1311-105A). At 18.5 days post-coitum, dams (n = 4 in each group) were euthanised and placentae harvested. Placentae were homogenized in TRIzol Reagent (GE Healthcare, Little Chalfont, UK) using GentleMACs™ Dissociator M-tubes (Miltenyi Biotec, Bergisch Gladbach, Germany) and RNA extracted by chloroform/isopropanol precipitation. One μg of total RNA was transcribed to cDNA using BioScript™ Reverse Transcriptase with Oligo(dT)18 primers (Bioline, London, UK) according to the manufacturer's instructions. Fpr2 mRNA was determined using the Fpr2-specific primers as previously described by Rondepierre et al. (2009) (Rondepierre et al., 2009) and SYBR Green PCR master mix (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol.
Real-time PCR
Total RNA from human placental tissues and cultured cells was extracted using the RNeasy Midi and Mini kits, respectively, as previously described (Murthi et al., 2006) . cDNA was prepared from 2 μg total RNA reversetranscribed using Superscript III ribonuclease H-reverse transcriptase (Invitrogen, Carlsbad, CA, USA) in a two-step reaction, also as previously described (Murthi et al., 2006 , Borg et al., 2015 . FPR2 mRNA expression was determined using validated assays that consisted of a TaqMan ® FAM™ labelled MGB probe (FPR2, Hs02759175_s1; HCGB, Hs00361224_gH; TP53, Hs01034249_m1; Casp8, Hs01018151_m1; C-X-C motif chemokine ligand 12 (CXCL12), Hs03676656_mH; C-X-C motif chemokine ligand 16 (CXCL16), Hs00222859_m1; C-X-C motif chemokine receptor 4 (CXCR4), Hs00607978_s1; C-X-C motif chemokine receptor 6 (CXCR6), Hs01890898_s1; C-X-C motif chemokine receptor 7 (CXCR7), Hs00664172_s1; C-X-C motif chemokine ligand 8, CXCL8 (IL8), Hs00174103_m1, IL-10, Hs00961622_m1, syncytin-2 (ERVFRD-1), Hs01942443_s1; BCL2, Hs00608023_m1 and BAX, Hs00180269_m1 (Thermo Fisher Scientific, Waltham, MA, USA) on an ABI Prism 7500 (Thermo Fisher Scientific, Waltham, MA, USA). Gene expression quantitation was performed as the second step in a two-step RT-PCR protocol according to the manufacturer's instructions. Gene expression quantitation for the house-keeping gene 18S rRNA (VIC-labelled probe, Thermo Fisher Scientific, Waltham, MA, USA) was performed in the same reaction as described previously (Murthi et al., 2006 , Borg et al., 2015 and the gene expression differences were calculated according to the 2 −ΔΔCT method (Livak and Schmittgen, 2001) . Furthermore, to quantitate the transcript copy number of FPR2 in first trimester, second trimester and in term placentae, the QuantStudio 3D Digital PCR system was used according to the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA, USA).
Immunoblotting
Total cellular and human placental tissue protein was extracted as previously described (Murthi et al., 2006 , Borg et al., 2015 . Immunoblotting was performed with 25 μg of total protein using 10% SDS/PAGE and electroblotting onto a nitrocellulose membrane (Pal Gelman, Hampshire, UK).
The membrane was blocked with 5% (w/v) skimmed milk for 1 h at room temperature, and followed by an overnight incubation at 4°C in 0.05 μg/μL rabbit anti-human polyclonal FPR2 (NLS 1878, Novus Biologicals, Littleton, USA) or 0.025 μg/μL rabbit anti-human polyclonal CXCR4 ( Antibody binding was visualized using horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse secondary antibody (0.02 μg/μL, Thermo Fisher Scientific, USA), followed by autoradiography using the ECLWestern Chemiluminescence Detection Kit (GE Healthcare, Little Chalfont, UK). Immunoreactive protein for FPR2 (38 kDa); CXCR4 (45 kDa); CXCR6 (39 kDa); CXCR7 (39 kDa), TP53 (53 kDa), Caspase 8 (55 kDa) and syncytin-2 (60 kDa) normalized to either the loading control, GAPDH (40 kDa) or tubulin (50 kDa) (ImageQuant, GE Healthcare, Little Chalfont, UK) was quantitated using scanning densitometry as described previously.
Immunohistochemistry
Assessment of the spatio-temporal distribution and localization of FPR2 protein in first-trimester and third-trimester FGR and control placental tissue sections was performed by immunohistochemistry as previously described (Murthi et al., 2006 , Borg et al., 2015 . Briefly, paraffin embedded 5 μm placental tissue sections were dewaxed in xylene, hydrated in graded ethanol (100-50% ethanol) and blocked with 1% bovine serum albumin (BSA) prepared in PBS. Tissue sections were then incubated overnight at 4°C with the primary antibody, either rabbit anti-human FPR2 or mouse monoclonal anti-CK7 (RCK 105 clone, Abcam, Cambridge, MA, USA), at a concentration of 0.01 μg/μL in 1% BSA/PBS. Control sections were incubated with 0.02 μg/μL mouse IgG or non-immune rabbit serum prepared in 1% BSA /PBS (DAKO, Copenhagen, Denmark). Chromogen detection was performed using 0.05% (w/v) 3,3′-diaminobenzidine (DAB) and 0.015% (v/v) hydrogen peroxide (Sigma-Aldrich, St Louis, MO, USA) and colour development was monitored under a light microscope. Slides were washed in distilled water, counterstained with hematoxylin, rehydrated in alcohol and Histoclear, and mounted in DPX (Sigma-Aldrich, St Louis, MO, USA) for imaging with a light microscope. All tissue sections were incubated with DAB for the same length of time so that comparisons could be made between individual samples, and all slides were stained in a single run to eliminate inter-experimental variations in staining intensity.
HUVEC cell proliferation assay
Cells were seeded in 96-well plates (2 × 10 4 cells/well, Corning) for 24 h.
Following siFPR2 or siCONT treatment of HUVEC, the proliferation potential of HUVEC was determined using the CellTiter 96 ® AQueous
One Solution Cell Proliferation assay (MTS assay, Promega Corporation, Madison, WI, USA) and the absorbance at 490 nm was recorded using an ELISA plate reader (SpectraMax i3, Molecular Devices, Sunnyvale, CA, USA). Further validation of the functional role of FPR2 on HUVEC cell proliferation was determined using the electrical impedance-based RTCA MP xCELLigence system (ACEA Biosciences Inc., San Diego, CA, USA). Briefly, 2 × 10 4 cells/well were plated onto a customised micro-gold electrode coated 96-well plate (ACEA Biosciences Inc., San Diego, CA, USA), placed within the xCELLigence system and placed in a humidified incubator maintained at 37°C with 95% air/5% CO 2 . The effect of FPR2 on cell proliferation was determined by treating cells with siFPR2. Control wells were treated with siCONT. Cell proliferation was monitored every 5 min for the first 4 h and thereafter every 15 min for 24 h as previously described (Borg et al., 2015) . A change in impedance caused by cell attachment and spreading is then expressed by the in-built software as an arbitrary cell index (CI).
Trophoblast differentiation assay
Trophoblasts were seeded in 6-well plates (2 × 10 5 cells/well), treated with siFPR2 or siCONT for 72 h, and the differentiation potential of trophoblast was determined by measuring the concentrations of β-hCG protein (Alpha Diagnostic International, Australia) in the culture media by ELISA at 450 nm on SpectraMax i3 (Molecular Devices, Sunnyvale, CA, USA) as previously described (Borg et al., 2015) . The minimum detection limit of this assay was 1.5 mIU/mL. An additional marker for trophoblast fusion was determined by using syncytin-2 (real-time PCR and immunoblotting) in trophoblasts treated with siFPR2 or siCONT for 72 h.
Human cytokine, chemokine and apoptosis cDNA arrays
Human cytokines, chemokines and apoptosis cDNA arrays (Applied Biosystems, Foster City, CA, USA) were used for gene profiling and to screen for genes that showed differential expression in primary trophoblasts treated with siFPR2 and siCONT. Briefly, cDNA was prepared and pooled from three independent experiments, then were added to a TaqMan master mix (Applied Biosystems, Foster City, CA, USA) and distributed in a TaqMan Array 96-well plate at~2 ng/well in a 20 μL reaction. The array plate contained 84 gene-specific primer sets with a panel of five house-keeping gene primers for normalization. The house-keeping genes consisted of 18S ribosomal RNA (18S rRNA), β-2-microglobulin, hypoxanthine phosphoribosyltansferase 1, GAPDH and β-actin. The PCR reaction was performed in the 7500 PCR System (Applied Biosystems, Foster City, CA, USA) under the following cycling parameters: 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s and primer extension at 60°C for 1 min. Data (Ct values) were analysed using the ABI Sequence Detector System software version 2.0 and the relative gene expression values were normalized to the five house-keeping genes using the DataAssist Software v3.0 (Applied Biosystems, Foster City, CA, USA). Candidate genes were identified from the fold-change differences observed in siFPR2-treated cells relative to siCONT-treated cells.
Cytokine assay
Trophoblasts were seeded in 6-well plates (2 × 10 5 cells/well), treated with siFPR2 or siCONT for 72 h, and cytokine concentrations in the culture media were quantified by Human Quantikine ELISA kits (R&D Systems, Minneapolis, USA) for the measurement of IL-6 (D6050); CXCL8 (IL8, HS800); C-X-C motif chemokine ligand 12, CXCL12 (DSA00); CXCL16 (DCX160) and IL-10 (M-1000B), following the manufacturer's instructions.
Endothelial tube assay
Endothelial tube formation was performed following the manufacturers' instructions (Ibidi, GmbH, Martinsried, Germany). Growth factor reduced Matrigel (Corning, NY, USA) was placed in a pre-chilled μ-slide angiogenesis wells (10 μL/well, Ibidi) and incubated at 37°C for 30 min. HUVEC cells in complete endothelial growth media-2 (EGM2, LONZA Bioscience, Basel, Switzerland) (20 000 cells in 50 μL) were treated with siFPR2 or siCONT for 6 h at 37°C, in 5% CO 2 . The culture medium was removed from the wells, and Calcein AM fluorescent dye (Merck Millipore, Billerica, Massachusetts, USA) diluted 1:500 with Hank's Balanced Salt Solution (HBSS 1:10, Thermo Fisher Scientific, Waltham, MA, USA) was added (40 μL/well). Tubes were assessed immediately through an inverted fluorescent microscope at ×4 (Olympus Corporation, Shinjiku, Tokyo, Japan) and quantitatively analysed (total tube lengths, branch points) using image J software (http://rsbweb.nih.gov/ij/; National Institutes of Health, Bethesda, MD, USA).
In vitro vascular permeability assay
Vascular permeability following siFPR2 or siCONT treatment in HUVEC was performed using the Millipore's fluorescence based In Vitro Vascular Permeability Assay kit following the manufacturer's instructions (Merck Millipore, Billerica, MA, USA). Briefly, HUVECs were plated on the inserts (50 000 cells/well) and cultured with 100 μL of EGM2 complete media in the upper chamber and 600 μL in the lower chamber at 37°C, 5% CO 2 for 72 h to form a tight monolayer. Cells were treated with either siFPR2 or siCONT for 48 h. The conditioned media were collected and 100 μL fresh media containing fluorescein isothiocyanate (FITC)-conjugated dextran (MW 40 000, final concentration 1 mg/mL, Sigma-Aldrich, St Louis, MO, USA) was added to the upper chamber, and the plate was incubated (protected from light) for 60 min. The media from the lower chamber were diluted (1:20) in HBSS for fluorescence measurement at 485/535 nm using an ELISA plate reader (SpectraMax i3, Molecular Devices, Sunnyvale, CA, USA). Results (fluorescence signals) are expressed as percentage changes relative to control.
Data analysis
All data were analysed using GraphPad Prism (version 7, GraphPad Software Inc., La Jolla, CA, USA). Gene and protein expression differences were analysed using Mann-Whitney U-test. A P value of <0.05 was considered to be statistically significant.
Results
Placental FPR2 expression across gestation
Real-time PCR analyses were performed using both relative quantitation to 18S rRNA (Fig. 1Ai ) and absolute quantitation (Fig. 1Aii) for copy numbers for FPR2 mRNA across gestation in first, second and in term placentae. Relative to term control, there was a 5-fold increase in FPR2 mRNA first-trimester placentae (Fig. 1Ai) and absolute quantitation further confirmed that FPR2 expression significantly declined as the gestation progressed (Fig. 1Aii) . As depicted in Fig. 1B , immunoreactive FPR2 protein was localized to VCT, ST, some SC and in the EVCT of the proximal cell column in the first-trimester placental tissues. No specific staining was observed in the negative control sections (Fig. 1C) .
Decreased placental FPR2 mRNA and protein in human FGR Placental FPR2 mRNA ( Fig. 2A ) and FPR2 protein expression (Fig. 2B) were significantly lower in third-trimester FGR placentae in comparison to gestation-matched control pregnancies. Immunohistochemistry studies revealed the presence of FPR2 protein predominantly in ST, EC surrounding the foetal capillaries and in some SC in FGR (Fig. 2C ) and in uncomplicated control (Fig. 2D ) term placentae. No immunoreactivity was observed in the IgG control (Fig. 2E ).
Placental Fpr2 mRNA is reduced in spontaneous FGR mouse model
As well as the CBA/CaH × DBA/2J murine model developing spontaneous FGR and foetal mortality, the placentae of (CBA/CaH × DBA/2J)F1 FGR fetuses show reduced weight, dimension, aberrant structure and the presence of histopathological changes associated with increased thrombosis and fibrosis (McKelvey et al., 2016) congruent with human FGR. For the present study, (CBA/CaH × DBA/2J)F1 fetuses weighing 30% less than (CBA/CaH × CaH/CaH)F1 were considered FGR (0.69 ± 0.08 FGR, versus 1.09 ± 0.02, P = 0.002). As shown in Fig. 2F , placental Fpr2 mRNA was significantly decreased in the FGR (CBA/CaH × DBA/2J)F1 compared to (CBA/CaH × CBA/ CaH)F1.
Reduced FPR2 contributes to increased trophoblast differentiation
The functional consequences of decreased FPR2 in FGR placentae were investigated in VCT isolated from uncomplicated third-trimester pregnancies using FPR2-specific siRNA (siFPR2) and non-targeted siRNA control (siCONT) (Fig. 3) . Following siFPR2 treatment, decreased FPR2 (40% reduction) was observed compared with siCONT at both the mRNA and FPR2 protein level in trophoblasts when maintained in culture for 72 h (Fig. 3A) . Trophoblast at 8-14 weeks of gestation (n = 12), 20 weeks of gestation (n = 4) and at term (n = 6). 18S rRNA was used as an internal control. Results are reported as the mean ± SEM. Data were analysed with Mann-Whitney U-test (significant differences (compared to 8-14 weeks), *P < 0.05). (Aii) Absolute quantitation of copy numbers for FPR2 was determined using the Digital PCR system. Data were analysed using one-way ANOVA, significant differences in FPR2 copy numbers in second trimester and term placentae were compared to first trimester, and is denoted by * or **P < 0. Representative immunoblot for FPR2 protein that compares gestation-matched control (n = 4) versus FGR placentae (n = 4). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for total protein loading control. Quantification of the intensity of the bands is illustrated in the bar graph. Results are reported as the mean ± SEM from n = 3 independent experiments. Data were analysed with Mann-Whitney U-test (significant differences, *P < 0.05). Immunohistochemical localization of FPR2 protein (as indicated by arrows) in ST, endothelial cells (EC) surrounding the foetal capillaries and in some SC in FGR (C) and in control (D) third-trimester placentae. No immunoreactivity was observed in the IgG control (E). Magnification of images at ×100. (F) Placental Fpr2 mRNA in the spontaneous FGR model. As described in the methods section, timed matings between 12-week old female CBA/CaH.Arc and male CBA/CaH.Arc and DBA/2J.Arc mice were undertaken. At 18.5 days post-coitum, placentae were homogenized and RNA was extracted. Fpr2 mRNA relative to 18S rRNA was quantified. Results are reported as the mean ± SEM from n = 4 from each group. Data were analysed with Mann-Whitney U-test (significant differences, *P < 0.05).
differentiation evaluated by HCGB mRNA (Fig. 3Bi ) and β-hCG protein (Fig. 3Bii) , and syncytin-2 mRNA and protein by immunoblotting and quantitation (Fig. 3C) , demonstrated significantly increased levels in siFPR2 compared with siCONT-treated cells.
Differential expression of cytokines and chemokines
A human cDNA array for cytokines, chemokines and apoptosis identified genes that are direct or indirect targets of FPR2. Candidate genes were prioritized ( Table I) for genes that showed a fold-change >1 or <1 of siCONT. As depicted in the cytokine array, IL-6 showed a significant increase in mRNA expression in siFPR2-treated cells, while IL-10 showed a significant decrease in mRNA expression in siFPR2 compared to siCONT. In the chemokine array, C-X-C motif chemokine ligand 8 (CXCL8) showed a significant increase in siFPR2-treated cells, while CXCL12, CXCL16, CXCR4, CXCR6 and CXCR7 showed a significant decrease in mRNA expression in siFPR2-treated trophoblasts when compared with siCONT. Real-time PCR validation demonstrated a significant decrease in CXCL12, and its receptors CXCR4 and CXCR7; CXCL16 and its receptor, CXCR6; and cytokine IL-10 ( Fig. 4A-F) , while the mRNA 1.00 ± 0.02 3.51 ± 0.54* Caspase 8 1.00 ± 0.03 1.54 ± 0.11* Notes: Data represent mean ± SEM (n = 3 per group). *P < 0.05 versus siCONT (paired sample comparison). FPR2, formyl peptide receptor 2; IL, interleukin; CXC, C-X-C motif chemokine; CXCL, C-X-C motif chemokine ligandl; CXCR, C-X-C motif chemokine receptor; TP, tumour protein.
expression of IL-6, CXCL8 ( Fig. 4G and H ) was significantly increased in siFPR2-treated cells compared with siCONT-treated trophoblasts. Analyses of protein concentrations or protein expression demonstrated a significant decrease in chemokines CXCL12, and its receptors CXCR4 and CXCR7; CXCL16 and its receptor, CXCR6; and cytokine IL-10 in siFPR2-treated trophoblasts when compared with siCONT ( Fig. 4I-N) . On the other hand, significantly increased protein concentrations or expression of IL-6 and CXCL8 were observed in siFPR2-treated trophoblasts when compared with siCONT ( Fig. 4O and P) . A representative immunoblot shows decreased protein expression of chemokine receptors CXCR4, CXCR6 and CXCR7 in siFPR2-treated trophoblasts compared with siCONT (Fig. 4Q) . Tubulin was used as loading control for both siFPR2 and siCONT-treated cells.
Differential expression of markers of apoptosis
In the apoptosis array, TP53 and caspase-8 both demonstrated a significant increase in apoptotic markers TP53 and caspase 8 (Table I) in siFPR2-treated cells compared with siCONT. Real-time PCR validation demonstrated a significant increase in apoptotic markers TP53, caspase 8 and BAX (Fig. 5A-C ) in siFPR2-treated cells compared with siCONTtreated trophoblasts. However, there was no significant change in BCL2 Figure 4 The effect of decreased FPR2 on the mRNA and protein expression of chemokines and cytokines in trophoblasts. Chemokine and cytokine mRNA expression was determined following siFPR2 and siCONT treatment of trophoblasts. (A-E) Real-time PCR validation for chemokine and cytokine mRNA relative to 18S rRNA: C-X-C motif chemokine ligand 12 (CXCL12); and its receptors, C-X-C motif chemokine receptor 4 (CXCR4); C-X-C motif chemokine receptor 7 (CXCR7); C-X-C motif chemokine ligand 16 (CXCL16) and its receptor, C-X-C motif chemokine receptor 6 (CXCR6) and cytokine interleukin10 (IL-10). (F and G) mRNA expression of interleukin-6 (IL-6) and C-X-C motif chemokine ligand 8, CXCL8 (interleukin-8, IL-8) relative to 18S rRNA. Chemokine and cytokine protein concentration and protein expression was determined following siFPR2 and siCONT treatment of trophoblasts. (H-M) Analyses of protein concentrations or the protein expression for chemokines CXCL12, and its receptors CXCR4 and CXCR7; CXCL16 and its receptor, CXCR6; and cytokine, IL-10. (N and O) Protein concentrations or expression of IL-6, CXCL8. A representative immunoblot for protein expression of chemokine receptors, CXCR4, CXCR6 and CXCR7 is shown in (Q). Data were analysed with Mann-Whitney U-test (significant differences, *P < 0.05).
in siFPR2-treated cells compared with siCONT-treated cells (Fig. 5D) . A representative immunoblot shows that the protein expression for apoptotic markers TP53 and caspase 8 was increased in siFPR2-treated trophoblasts compared with siCONT (Fig. 5E ). Tubulin was used as a loading control for both siFPR2 and siCONT-treated cells.
Decreased FPR2 contributes to EC dysfunction in HUVEC
The role of FPR2 in HUVEC was also studied following siFPR2 transfection. The efficacy of transfection is demonstrated in Fig. 6 . There was a significant reduction in FPR2 mRNA expression (71% decrease) and protein expression (54% decrease) in siFPR2-treated HUVEC compared with siCONT-treated cells (Fig. 6A) . Following siRNA treatment, HUVEC cell proliferation as measured by the MTS assay demonstrated a significant decrease in the proliferative potential of HUVEC in siFPR2-treated cells compared to siCONT-treated cells (1.92 ± 0.07 (siCONT) versus 1.50 ± 0.05 (siFPR2), n = 6, P < 0.05). Further validation using the xCELLigence system demonstrated that the CI was significantly decreased in siFPR2-treated cells compared with siCONT, as depicted in Fig. 6B . Functional consequences of decreased FPR2 on HUVEC following siRNA treatment demonstrated a disruption in Figure 4 Continued network formation ability (Fig. 6C) and further quantitation revealed a significantly decreased number of branching points in siFPR2-treated cells compared with siCONT (Fig. 6D) , while the vascular permeability potential in HUVEC monolayer cultures was significantly increased in siFPR2-treated cells compared with siCONT (Fig. 6E) .
Discussion
Aberrant trophoblast differentiation, increased apoptosis, unbranched angiogenesis and endothelial dysfunction are hallmarks of FGR (Roberts  et al., 2004, Heazell et al., 2011, Larque et al., 2013) . However, the Figure 5 The effect of decreased FPR2 on the protein concentrations and expression of apoptotic markers in trophoblasts. The mRNA and protein expression of apoptotic markers were determined following siFPR2 and siCONT treatment of trophoblasts. (A-C) Apoptotic markers, tumour protein 53 (TP53), caspase 8 and BCL associated X (BAX) mRNA expression relative to 18S rRNA. Results are reported as the mean ± SEM from n = 6 independent experiments. (D) B cell lymphoma 2 (BCL2) mRNA expression relative 18S rRNA. (E). A representative immunoblot for protein expression of apoptotic markers TP53 and caspase 8 in siFPR2-treated trophoblasts compared with siCONT. Tubulin was used as a loading control for both siFPR2 and siCONT-treated cells. Results are reported as the mean ± SEM from n = 6 independent experiments. Data were analysed with MannWhitney U-test (significant differences, *P < 0.05; NS, non significance).
causes of such dysfunction are not fully understood. The present study provides evidence that FGR is associated with a deficiency of FPR2, a high-affinity GPCR. In this study, we report that FPR2 mRNA is expressed in the human placenta throughout gestation. We have also demonstrated that FPR2 mRNA and protein expression is decreased in a clinically well-defined cohort of FGR pregnancies that were carefully selected using strict clinical criteria indicative of placental insufficiency and underlying pathology (Murthi et al., 2006 , Borg et al., 2015 . Notably, placental FPR2 expression is also reduced in PE-affected pregnancies and administration of a synthetic antagonist of FPR2 peptide to pregnant rats significantly reduced birthweight in the offspring (Xu et al., 2014) , suggesting FPR2 mediated signalling is critical for foetal growth. Results are reported as the mean ± SEM from n = 6 independent experiments. Data were analysed with Mann-Whitney U-test (significant differences, *P < 0.05).
Fpr2 expression in the spontaneous FGR mouse
We have also demonstrated that Fpr2 was decreased in the placentae of FGR fetuses in the spontaneous CBA/CaH × DBA/2J murine model. In murine studies, Fpr2 deficiency reduces the differentiation, maturation and trafficking of antigen-presenting dendritic cells (Chen et al., , 2014 and limits M2 polarization of macrophages (Mills et al., 2000 . Both of these cell types contribute to the suppression of Th1 cells during uncomplicated pregnancies. Therein, the reduction of Fpr2 in murine FGR placentae may skew the spatial and temporal distribution of the immune infiltrate toward the prolonged presence of Th1 cells and M1 macrophages, contributing to maternalfoetal allograft rejection and FGR. In the context of our other results, it is important to note that dysregulation of utero-placental immunity during early pregnancy can have a profound effect on placentation as macrophages, T-lymphocytes and natural killer cells actively regulate spiral artery formation and uterine remodelling (Brown et al., 2014) .
FPR2-dependent trophoblast differentiation and apoptosis
The mechanism by which FPR2 contributes to foetal growth is largely unknown. Here in this study, we have provided evidence that FPR2 is important for both trophoblast and endothelial function in the human placenta. Our study demonstrated the presence of FPR2 mRNA in primary VCT from term placentae. The ST layer is a major site for numerous important placental functions, including nutrient and ion exchange, and the synthesis of steroid and peptide hormones required for foetal development and growth (Lager and Powell, 2012; Pidoux et al., 2012) . Here, we have used primary VCT from third-trimester placentae to determine the effect of FPR2 on in vitro differentiation. FPR2 siRNA treatment in primary VCT demonstrated that FPR2 is involved in the regulation of ST differentiation, as demonstrated by a significant increase in mRNA and protein expression of HCGB and syncytin-2. Placental protein, including β-hCG as a measure of placental volume and function, is used a predictive marker of pregnancy outcomes. Previous reports observed that free β-hCG in first-trimester maternal serum was mildly reduced in pregnancies that subsequently developed FGR later in pregnancy (Dugoff et al., 2005) . However, few studies also reported that high levels of maternal free β-hCG in the second trimester are associated with poor pregnancy outcome, including SGA and PE (Wenstrom et al., 1994) (Sebire et al., 2000) . Although, even if the predictiveness of maternal serum hCG protein as a single biomarker in FGR was reported as unsatisfactory (Dugoff et al., 2005) , it was suggested that altered placental perfusion and placental damage during the second trimester may trigger the over-production of β-hCG by ST (Sebire et al., 2000) . Our own previous studies have demonstrated that placental chorionic villi from third-trimester FGR pregnancies are associated with up-regulated expression of HCGB mRNA and β-hCG protein (Chui et al., 2012) , this was also consistent with earlier reports by (Newhouse et al., 2007) , where it was demonstrated that in vitro differentiation of VCT from FGR-affected pregnancies was associated with significantly higher levels of syncytialization and hormone secretion, including β-hCG compared to trophoblasts derived from uncomplicated pregnancies.
We have also further demonstrated in this study that aberrant differentiation following siFPR2 treatment in primary term trophoblasts is also associated with an increased mRNA expression of the apoptotic markers, TP53, caspase 8, BAX. Previous studies have shown that increased trophoblast shedding and apoptosis are associated with FGR pregnancies (Heazell et al., 2011) . Our studies are also consistent with previous reports by Ishihara et al. (2002) in the placental villi from FGR-affected pregnancies, where an elevated expression for the proapoptotic marker BAX was reported but no significant change in the anti-apoptotic marker BCL2 was observed (Heazell et al., 2008) . The decreased expression of FPR2 in FGR, therefore, may have clinical significance in contributing to the premature depletion of the pool of proliferating VCT by favouring their premature differentiation to ST and leading to increased trophoblast shedding and apoptosis in FGR (Kingdom et al., 2000; Huppertz et al., 2006) .
FPR2-dependent placental cytokine and chemokine expression
FPR2 is a known regulator of resolution of inflammation, a process which is vital for tissue homoeostasis (Perez et al., 2014) . Mice deficient in Fpr2 exhibit exacerbated disease in carrageenan-induced paw oedema and K/BxN serum transfer-induced arthritis (Dufton et al., 2010) , indicating that FPR2/Fpr2 mediates anti-inflammatory effects. FPR2 regulates inflammatory events in the human endometrium and decidua of early pregnancy by facilitating the delicate balance in the production of pro-and anti-inflammatory cytokines for tissue homoeostasis (Macdonald et al., 2011) . Cytokines and chemokines expressed in human trophoblasts play an integral role in placentation, by regulating both immune and non-immune functions of placenta (Huang et al., 2006 , Wang et al., 2015 . Higher levels of T-helper (Th) 1 (pro-inflammatory) cytokines have been observed in pregnancies complicated with FGR; this is in contrast to the predominant Th2 (anti-inflammatory) cytokine environment found in uncomplicated pregnancies (Street et al., 2009 ). Furthermore, Hahn-Zoric et al. (2002 reported higher placental levels of the chemokine CXCL8 in placentae from FGR-affected pregnancies compared with placentae from uncomplicated control pregnancies. It has been suggested that local action of chemokines may be responsible for the increased infiltration of macrophages into the placenta that is seen in FGR, and activated macrophages could contribute to placental dysfunction (Li and Huang, 2009 ). These findings suggest that in trophoblast, FPR2 may have a direct or indirect role in the regulation of the genesis/actions of cytokines and chemokines.
Deficiency of murine Fpr2 in an acute liver injury model is associated with an increased apoptosis of hepatic cells and a reduced regenerative capacity (Giebeler et al., 2014) . Increased trophoblast apoptosis is a hallmark of FGR placentae (Heazell et al., 2011) . Although there are several molecular pathways that contribute to trophoblast apoptosis and cell survival (Heazell et al., 2011) , our findings suggest a role for reduced FPR2 as a potential novel mechanism for trophoblast apoptosis in FGR placentae. However, the specific signalling pathway by which FPR2 contributes to trophoblast apoptosis is yet to be investigated. In other cell types, activation of FPR2 by specific ligands increases cell proliferation and survival by eliciting distinct signalling pathways (Cattaneo et al., 2013) . For example, binding to lipoxin A4 and/or Annexin A1, FPR2 activates the serine/threonine kinase, specifically PI3K-Akt/PKB or MEK/ERK signalling pathways to promote tumour cell survival and proliferation (Cattaneo et al., 2013) .
FPR2-dependent change in vascular EC function
In this study, we have also demonstrated that FPR2 influences many distinct functions depending on its localization within the placenta. A reduction in the expression of FPR2 in EC resulted in a decrease in proliferation and in their ability to form a network for the establishment of new blood vessels. Placental vascular formation is important for foetal growth and development. Proper development of the placenta ensures the exchange of oxygen/nutrients and blood flow necessary for foetal growth. Chen et al. (2002) showed a significant decrease in villous vascular density within the FGR placentae, suggesting a decrease in branching angiogenesis during this disease. Other reports have demonstrated a decrease in surface area, volume, and number of terminal villi as well as a reduced number of capillaries in the stroma of FGR placentae as compared with placentae from normal pregnancies (Macara et al., 1995 Krebs et al., 1996) . These findings suggest that aberrant vascular formation could be a factor associated with the increased umbilical artery blood flow resistance observed in FGR pregnancies. Thus, reduced FPR2 in placental EC may contribute to the vascular abnormalities associated with idiopathic FGR pregnancies.
Placental villous development requires the co-ordinated action of pro-and anti-angiogenic factors for maintenance of vascular functions including vascular permeability (Dunk and Ahmed, 2001) . In this study, we have demonstrated that decreased FPR2 expression in HUVEC led to an increase in membrane permeability potential suggesting FPR2 may contribute to the pathophysiological mechanisms associated with feto-placental dysfunction in FGR pregnancies. Endothelial integrity is critical for nutrient transport across the placenta for maximal foetal growth. The transfer of membrane permeable molecules, such as oxygen and carbon dioxide, is greatly influenced by blood flow and placental structure. Larger and less membrane permeable substances rely on transporter proteins to cross the placenta, in a process fuelled by ionic gradients (Lager and Powell, 2012) . Therefore, it is possible that low FPR2 levels could influence vascular permeability in feto-placental vessels, thereby contributing to the pathophysiological mechanisms associated with poor nutrient transport leading to FGR.
Limitations and future directions
Our study has demonstrated the clinical significance of placental FPR2/ Fpr2 in FGR pregnancies, as well as the biological significance of FPR2 in placental cell function using in vitro and in vivo models of FGR. Future studies on placental specific deletion of Fpr2 in mice may provide evidence for a direct regulatory role of Fpr2 on placental development. FPR2 shows complex functional properties, partly due to its high promiscuity and also the fact that its activation can stimulate several signal transduction pathways, depending on the ligand, its concentration and the cell types involved (Macdonald et al., 2011; Cattaneo et al., 2013; Kao et al., 2014; Perez et al., 2014) . Several endogenous FPR2 ligands, including lipoxin A4, annexin A1 and mitochondrial peptides, have already been recently identified as potential therapeutic targets for inflammatory diseases (Cattaneo et al., 2013) . Upon binding to specific ligands, FPR2 activates phospholipase C, protein kinase C isoforms, the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, the mitogen-activated protein kinase (MAPK) pathway, and p38MAPK, as well as the phosphorylation of cytosolic tyrosine kinases, tyrosine kinase receptor transactivation, phosphorylation and nuclear translocation of regulatory transcriptional factors, and release of calcium and production of oxidants (Cattaneo et al., 2013) . Understanding the specific signalling pathways directly regulated by FPR2 that are critical for trophoblast and EC proliferation, cell survival and protection against cell death, regulation of oxidative stress, transcriptional factor complex activation and regulation of angiogenesis may provide avenues to improve placental cell function in physiological and in pathological pregnancies including FGR, and may also provide identification of targeted therapeutics to improve pregnancy outcome.
Conclusion
Our data demonstrate that FPR2 may play an important role in placentation in human FGR. Reduced expression of placental Fpr2 is associated with spontaneous FGR in a mouse model. Our in vitro studies using human placental trophoblast and EC provide evidence for a crucial role of FPR2 in the placental pathogenesis of FGR.
